In preclinical models of melanoma, 2-DG decreases TAM expression of Arg1, Fizz, Mrc1 (encoding CD206), and Vegf, indicating that 2-DG diminishes immunosuppression within the TME (46). This evidence concerns the gene MRC1 and melanoma.